APG-115 (AA-115) is a compound designed by Aguilar et al. to address the slow isomerization of SAR405838 in solution; it can rapidly and irreversibly convert into a single non-racemic isomer, exhibiting better oral pharmacokinetic properties and a higher IC50 value, effectively inhibiting the growth of wild-type p53 human cancer cell lines at low concentrations [154]. Here, TP53 is linked to cancer.